These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19242379)

  • 21. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
    Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
    Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M
    Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
    Cheadle EJ; Gilham DE; Thistlethwaite FC; Radford JA; Hawkins RE
    Br J Haematol; 2005 May; 129(3):322-32. PubMed ID: 15842655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
    French RR; Chan HT; Tutt AL; Glennie MJ
    Nat Med; 1999 May; 5(5):548-53. PubMed ID: 10229232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
    Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
    Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoxetine directly counteracts the adverse effects of chronic stress on T cell immunity by compensatory and specific mechanisms.
    Frick LR; Rapanelli M; Cremaschi GA; Genaro AM
    Brain Behav Immun; 2009 Jan; 23(1):36-40. PubMed ID: 18625298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting antigen to CD19 on B cells efficiently activates T cells.
    Yan J; Wolff MJ; Unternaehrer J; Mellman I; Mamula MJ
    Int Immunol; 2005 Jul; 17(7):869-77. PubMed ID: 15967786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
    Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
    Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells.
    Oizumi S; Deyev V; Yamazaki K; Schreiber T; Strbo N; Rosenblatt J; Podack ER
    J Immunother; 2008 May; 31(4):394-401. PubMed ID: 18391756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive cellular immunotherapy with CD19-specific T cells.
    Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
    Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand.
    Liu A; Guardino A; Chinsangaram L; Goldstein MJ; Panicali D; Levy R
    Cancer Res; 2007 Jul; 67(14):7037-44. PubMed ID: 17638917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
    Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
    J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
    Lee JC; Hayman E; Pegram HJ; Santos E; Heller G; Sadelain M; Brentjens R
    Cancer Res; 2011 Apr; 71(8):2871-81. PubMed ID: 21487038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD8(+) T cells specific for beta cells encounter their cognate antigens in the islets of NOD mice.
    Pang S; Zhang L; Wang H; Yi Z; Li L; Gao L; Zhao J; Tisch R; Katz JD; Wang B
    Eur J Immunol; 2009 Oct; 39(10):2716-24. PubMed ID: 19658094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
    Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
    Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterisation of soluble murine CD137 and its association with systemic lupus.
    Shao Z; Sun F; Koh DR; Schwarz H
    Mol Immunol; 2008 Sep; 45(15):3990-9. PubMed ID: 18640726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.